Zobrazeno 1 - 5
of 5
pro vyhledávání: '"HIFMECH Study Group"'
Autor:
Kelberman D, Hawe E, Luong LA, Mohamed Ali V, Lundman P, Tornvall P, Aillaud MF, Juhan Vague I, Yudkin JS, Margaglione M, Tremoli E, Humphries SE, HIFMECH study group, DI MINNO, GIOVANNI
Publikováno v:
Thrombosis and Haemostasis. 92:1122-1128
SummaryElevated plasma IL-6 levels have been implicated in the pathogenesis of coronary heart disease. We have investigated the association of two polymorphisms in the promoter of IL-6 (-572G>C and -174G>C) with levels of inflammatory markers and ris
Autor:
Morange, P.E., Saut, N., Alessi, M.C., Frere, C., Hawe, E., Yudkin, J.S., Tremoli, E., Margaglione, M., Di Minno, G., Hamsten, A., Humphries, S.E., Juhan Vague, I., HIFMECH Study Group
Experimental and clinical observations suggest that innate immunity plays a major role in the pathogenesis and progression of atherosclerosis. A common C-260T polymorphism in the promoter of the CD14 gene, the trans-membrane receptor of lipopolysacch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b67c0c680525d335c97b76f21b9aab9
http://hdl.handle.net/11588/477077
http://hdl.handle.net/11588/477077
Autor:
Konstantoulas C, Hawe E, Saut N, Yudkin JS, Margaglione M, Hamsten A, Humphries SE, Juhan Vague I, Ireland H, HIFMECH Study Group, DI MINNO, GIOVANNI
Publikováno v:
Thrombosis and haemostasis. 91(3)
Common variants in the thrombomodulin gene as a risk for myocardial infarction in the north of Europe (HIFMECH Study)
Autor:
Juhan Vague I, Morange PE, Frere C, Aillaud MF, Alessi MC, Hawe E, Boquist S, Tornvall P, Yudkin JS, Tremoli E, Margaglione M, Hamsten A, Humphries SE, HIFMECH Study Group, DI MINNO, GIOVANNI
Summary. Although the potential role of plasminogen activator inhibitor-1 (PAI-1) in the development of coronary artery disease is strongly supported by its biological characteristics, results of clinical studies remain controversial. Objectives: To
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb63eb0611c731a864962b08d4985cd3
http://hdl.handle.net/11588/477070
http://hdl.handle.net/11588/477070
Autor:
Juhan Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC, Samnegård A, Hawe E, Yudkin J, Margaglione M, Hamsten A, Humphries SE, HIFMECH Study Group, DI MINNO, GIOVANNI
The thrombin-activatable fibrinolysis inhibitor (TAFI) is a recently described inhibitor of fibrinolysis that decreases plasminogen binding to the fibrin surface. The plasma TAFI concentration is almost entirely genetically determined. We investigate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::016262a9395c2f8820bbc785dec3f5a7
http://hdl.handle.net/11588/477208
http://hdl.handle.net/11588/477208